09:48 AM EST - Helix BioPharma Corp. : Will present new preclinical data on L-DOS47 in combination with PD1 checkpoint inhibition at the 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in the Hynes Convention Center, Boston, via in person attendance, October 11-15. Helix BioPharma Corp.
shares T.HBP are trading unchanged at $0.21.
